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The ability of mesenchymal stromal cells (MSCs) to suppress immune responses combined with their potential to actively
participate in tissue repair provides a strong rationale for the use of MSCs as a new treatment option in diseases characterized by
inflammation and severe tissue damage, such as Crohn’s disease (CD) and perianal fistulas. Multiple studies have shown that MSCs
suppress a range of immune cells, such as dendritic cells (DC), naı¨ve and effector T cells, and natural killer (NK) cells. Recently
published papers attribute the immunosuppressive capacity of MSCs to soluble factors produced by MSCs, such as prostaglandin
E2 (PGE2), inducible nitric oxide synthase (iNOS), and indoleamine 2,3-dioxygenase (IDO). Promising results are obtained from
phase I and II clinical trials with autologous and allogeneic MSCs as treatment for refractory CD and perianal fistulas; however
the question remains: what are the molecular mechanisms underlying the immunomodulating properties of MSCs? This paper
highlights the present knowledge on the immunosuppressive effects of MSCs and its complexity in relation to CD and perianal
fistulas.
1. Crohn’s Disease
Crohn’s disease (CD) and ulcerative colitis (UC), collec-
tively called inflammatory bowel disease (IBD), are chronic
diseases characterized by idiopathic inflammation of the
gastrointestinal tract. The peak age of onset for CD is 15–
30 years, without gender preference [1]. An inappropriate
immune response to extracellular pathogens in the gut in a
genetically predisposed host, for example, NOD2/CARD15
gene associated, is thought to be the cause of IBD [2, 3].
However, the exact etiology remains unclear. The incidence
of CD has classically been higher in developed countries;
however, urbanization and modernization of undeveloped
countries seem to increase the incidence of CD to a similar
level as the developed countries [4]. CD can affect any part of
the intestine, from mouth to anus, but preferentially involves
the ileum and colon. Characteristic for CD are skip lesions;
inflamed parts of the intestine interspersed by apparent
normal healthy tissue.
Patients with CD can suffer from diarrhea (with blood
or mucus), abdominal pain, fever, weight loss, nausea,
vomiting, and fatigue [5]. Frequent complications in CD
are abscess and stricture formation, intestinal obstruction,
and fistulas [2–6]. Fistulas are abnormal connective passages
from the epithelial lining of the intestines to another organ
or to the skin caused by inflammation. At least one fistula
episode (54% perianal) was diagnosed in 35% of CD
patients in a large cohort from Minnesota with a follow-
up time of 25 years [7]. Patients with perianal fistulas have
symptoms like pain, discharge, incontinence, and perineal
and genital disfigurement [8]. The diagnosis of CD is
established by the clinical features confirmed by endoscopy.
Biopsy specimens from inflamed gut mucosa typically show
transmural inflammation, including submucosal oedema,
ulcerations, and fibrosis.
The choice of medical treatment depends on the loca-
tion of disease, its severity, and response to earlier ther-
apy. Immunosuppressive therapy (e.g., 6-mercaptopurine,
azathioprine, and methotrexate) and biological anti-TNF-α
therapies (e.g., infliximab and adalimumab) are mostly used
to treat active disease and prevent relapses. Unfortunately,
70%–90% of the patients will eventually need surgery during
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the course of the disease, because the disease responds
less to medical therapies over time. Approximately 39% of
the patients with CD will even require repeated surgery
[9]. An anti-TNF-α therapy is the first choice in the
treatment of patients with perianal fistulas. However, even
with treatment, perianal fistulas often lead to physical and
emotional distress and only in 46% of the cases perianal
fistulas heal completely [10]. The surgical approach tries
to control infectious complications by drainage of abscesses
by placement of noncutting silastic setons. Sometimes fecal
diversion is needed (stoma) to attenuate perianal symptoms.
When these goals have been reached, surgery is aimed to
eradicate the fistula while preserving fecal continence. In
this latter phase, surgery depends upon the type of fistula
and its anatomical extent. Standard surgical approaches are
fistulotomy or a mucosal advancement plasty, which are
unsuccessful in over 50% of the cases [11]. Effective medical
therapeutics for patients with CD and perianal fistulas,
refractory to or dependent on the conventional strategies, are
needed.
To investigate new therapeutic options for CD, two
mouse models are most commonly used to induce colitis
[12, 13]. In the most frequently used model, dextran sulfate
sodium (DSS) polymers are added to drinking water for
several days. This is directly toxic to gut epithelial cells of
the basal crypts and affects the integrity of the mucosal
barrier. This acute colitis is characterized by ulcerations,
bloody diarrhea, and infiltration with granulocytes and
is particularly useful to study the contribution of innate
immune mechanisms to colitis [12, 13]. Colitis can also
be induced by intrarectal administration of the haptenizing
agent 2,4,6-trinitrobenzene sulfonic acid (TNBS) diluted in
ethanol [12–14]. Ethanol is necessary to break down the
mucosal barrier, whereas TNBS haptenizes the microbial
flora in the colon in order to stimulate an immune response.
This model is useful to study T helper cell-dependent
mucosal immune responses since CD4+ T cells have been
shown to play a key role in TNBS colitis [13].
2. Mesenchymal Stromal Cells
In addition to hematopoietic stem cells, the bone marrow
also contains mesenchymal stromal cells (MSCs) [15]. These
MSCs are multipotent cells, capable of differentiating into
multiple lineages of the mesenchyme, including osteoblasts,
adipocytes, and chondroblasts [16–18]. Apart from the bone
marrow, MSCs have been isolated from several other tissues,
such as adipose tissue [19], peripheral blood [20], umbilical
cord blood [21], and placenta [22]. Recently MSCs have also
been isolated from gingiva (gMSCs), a unique oral tissue
attached to the alveolar bone of tooth sockets [23]. Not only
is the oral cavity easily accessible, but gMSCs can also be
easily obtained from discarded tissue from routine dental
procedures. According to the minimal criteria proposed by
the International Society for Cellular Therapy [24], MSCs
should be identified based on their ability to adhere to
plastic in standard culture conditions and on their ability
to differentiate in vitro into bone, fat, and cartilage. They
must express CD73, CD90, and CD105 and may not express
CD11b or CD14, CD19, CD45, CD79α, and HLA-DR surface
molecules. These MSCs possess a unique combination of
functional activities, that is, they have the ability to suppress
immune responses and they are able to actively participate
in tissue repair processes. The ability of MSCs to suppress
immune responses could be relevant in the treatment of
luminal CD, whereas in the case of perianal fistulas their
potential to repair tissue is thought to be more important
[25]. In addition, MSCs are immunologically relatively inert
since they are poor antigen presenting cells (APCs) and
do not express MHC class II or costimulatory molecules.
In accordance, expanded MSCs do not stimulate T-cell
proliferation in mixed lymphocyte reactions (MLRs) and are
also able to downregulate alloreactive T-cell responses when
added to mixed lymphocyte cultures [18, 26–29]. These find-
ings suggest that allogeneic MSCs could be very useful in the
clinic and their expansion potential provides the possibility
to generate a stock with “off the shelf-”treatment potential.
However, in contrast to the general idea that MSCs are not
immunogenic, Nauta et al. showed that multiple injections
of allogeneic MSCs after bone marrow transplantation in
sublethally irradiated mice decrease engraftment whereas
syngeneic MSCs promote engraftment [30]. In addition,
allogeneic MSCs are capable of inducing a memory T-
cell response in immunocompetent hosts. Although further
studies are needed to elucidate the situations wherein MSCs
can be immunogenic, these findings should be taken into
account when allogeneic MSCs are used in clinical setting.
Furthermore, MSCs have been shown to alter cytokine
secretion profiles of dendritic cells (DC), naı¨ve and effector
T cells, and natural killer (NK) cells, which is accompanied
by the induction of a more anti-inflammatory or tolerant
phenotype [31].
3. MSCs and Antigen Presenting Cells
Allogeneic human MSCs (hMSCs) have a reversible
inhibitory effect on the differentiation of monocytes into
DCs [32–34] and are able to downregulate the expression
of the costimulatory molecules CD80 and CD86 in the
case of mature DCs. DCs that are cocultured with MSCs
before adding them to T cells show a reduced ability to
activate these T cells to proliferate [32]. When hMSCs are
cocultured with unmatched peripheral blood mononuclear
cells (PBMCs), hMSCs reduce T-cell proliferation and the
secretion of interferon-gamma (IFN-γ) by these cells, which
is normally induced upon coculture with allogeneic cells
[27, 33]. In addition, IFN-γ secretion and T-cell proliferation
can be partially restored when lipopolysaccharides (LPS)
or anti-CD40 monoclonal antibodies, which both promote
APC-maturation, are added to cocultures with hMSCs. This
suggests that hMSCs may have an effect on normal APC
maturation [33]. Furthermore, Aggarwal and Pittenger [31]
showed a significant decrease of 50% in TNF-α secretion
in response to LPS when type 1 DCs are cocultured
with hMSCs. Upon LPS stimulation, type 2 DCs secrete
moderate levels of IL-10, an anti-inflammatory cytokine.
Interestingly, when cocultured with hMSCs, the percentage
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of IL-10 increases with 140%. These results suggest that
hMSCs cocultured with matured DCs provide a more anti-
inflammatory milieu in vitro.
4. MSCs and T Cells
In the same paper, Aggarwal and Pittenger [31] describe
the interaction between MSCs and T cells. Naı¨ve T cells
were activated to differentiate into T helper cell type 1
(Th1) or T helper cell type 2 (Th2) in the presence or
absence of hMSCs. A significant decrease of 60% in levels
of IFN-γ was seen when hMSCs were present during the
differentiation into Th1 cells compared to differentiation
without hMSCs.Moderate levels of IL-4 were secreted during
the differentiation of naı¨ve T cells into Th2 cells, a cytokine
known to induce this T-cell differentiation. The average
increase in the amount of IL-4 in the presence of hMSCs
during this differentiation process was 500%, suggesting
that hMSCs provide significant help for naı¨ve T cells to
differentiate into Th2 cells.
Anergic T cells express the IL-2 receptor, but do not
proliferate or produce IL-2 in response to adequate antigenic
stimulation. Normally, this anergic state can be abolished by
the addition of exogenous IL-2. However, MSCs can induce
a anergic state in T cells that is only partially reversible, also
known as a split anergic state [35, 36]. Glennie et al. [35]
showed that after addition of IL-2 and removal of MSCs,
IFN-γ production was restored; however, the proliferation of
PBMCs was not.
A naturally anergic and suppressive T-cell population
that induces immunologic self-tolerance and plays a key role
in the development of autoimmune diseases, such as IBD, are
CD25+CD4+ cells [37]. Maccario et al. [38] demonstrated
a large increase in the number of CD4+CTLA-4+ and
CD4+CD25+CTLA-4+ cells in the presence of third-party
MSCs and a slight increase in these subsets in the presence
of autologous MSCs compared to control. CTLA-4 is a T
cell inhibitory receptor involved in mediating T cell anergy
and tolerance [39]. These observations indicate that MSCs
increase the levels of a regulatory T cell (Treg) phenotype
which suppresses Th1 immune responses. In a TNBS model,
systemic infusion of adipose-derived MSCs (adMSCs) has
been reported to ameliorate the clinical and histopathologic
severity of TNBS colitis [40]. This therapeutic effect was
found to be mediated by down-regulating TNF-α, IFN-γ,
IL-1β, IL-6, and IL-12 and on the other hand elevating
regulatory cytokine IL-10 in colonic tissue. A second paper
from the same group [41] corroborated these data by
showing that systemic infusion of adMSCs protects against
experimental DSS colitis and sepsis. An increased number of
FoxP3+ was not only described in colon tissue but also in
mesenteric lymph nodes (MLNs) [42]. Mice intravenously
treated with bone marrow-derived MSCs (bmMSCs) after
induction of colitis with TNBS had an approximately 2.1-fold
higher absolute number of CD25+FoxP3+ cells compared to
control mice.
Besides Th1 and Th2 cells, a subset of Th cells that
produces high levels of IL-17 exists. These so-called Th17
cells protect against extracellular pathogens at mucosal
surfaces and are thought to play an important role in
inflammation and tissue damage in autoimmune diseases
such as CD. During the differentiation of naı¨ve T cells into
Th17 cells, the presence of MSCs inhibits the production of
inflammatory cytokines and slightly induces the production
of IL-10 and concomitantly strongly enhances the expression
of FoxP3 mRNA levels. Additionally, the presence of MSCs
in a culture with stimulated fully differentiated Th17 cells
results in decreased levels of IL-17 and IL-22, increased IL-
10 production, and, again, enhanced FoxP3 mRNA levels.
The induction of FoxP3 mRNA expression gives rise to
a functional Treg phenotype, which is confirmed by the
observed ability of Th17 cells to inhibit proliferation of T
cells during coculture withMSCs. In contrast, Th17 cells that
have not been in contact with MSCs do not have an effect
on the proliferation of T cells [43]. Liang et al. [44] revealed
that human umbilical cord MSCs (ucMSCs) in coculture
can significantly inhibit IL-17 production by lamina propria
mononuclear cells and splenocytes. In a TNBS model, these
in vitro results were confirmed, that is, ucMSC-treated mice
had significantly lower levels of IFN-γ, IL-6, IL-17, and IL-23
in the colon compared to the control mice.
5. MSCs and NK Cells
NK cells are cytotoxic effector cells of the innate immune
system that play a key role in the elimination of virally
infected or transformed cells. Upon stimulation with IL-2,
purified NK cells produce IFN-γ and when these stimulated
NK cells are subsequently cocultured with hMSCs, the levels
of secreted IFN-γ decreases with 80% [31]. Furthermore,
allogeneic MSCs inhibit IL-2- and IL-15-induced prolifera-
tion of resting NK cells. However, they seem to have only
a partial inhibitory effect on already proliferating NK cells.
Intriguingly, autologous and allogeneic NK cells stimulated
with IL-2, but not freshly isolated NK cells, show a strong
cytolytic activity against MSCs. MSC pretreated with IFN-γ,
however, are less susceptible to lysis by the NK cells [45].
Although MSCs are able to alter cytokine secretion
profiles of different immune cells in order to induce a
more anti-inflammatory or tolerant phenotype, the question
remains: what are the mechanisms by which MSCs exert
this biological activity? Several studies suggest that MSC-
derived soluble factors may contribute to this induced
immunosuppression [26, 29].
6. Prostaglandin E2 (PGE2)
PGE2 is one of the immunosuppressive molecules produced
by MSCs when activated by inflammatory cytokines such
as IFN-γ and TNF-α [31]. Non-bone marrow-derived lam-
ina propria stromal cells constitutively produce COX-2-
dependent PGE2, as shown by Newberry et al. [46], which
suggests that the expression of inflammatory mediator COX-
2 by lamina propria stromal cells contributes to the low
immune response against antigens in the mucosa of the small
intestine. The ability of MSCs to inhibit Th17 differentiation
and to induce a regulatory phenotype is strongly believed to
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be mediated by the COX-2-dependent soluble factor PGE2
(Duffy et al. [47]). In an experimental arthritis model,
Bouffi et al. [48] demonstrated that MSCs do not only
have a local immunosuppressive effect but also a systemic
are. Secreted PGE2 was the main factor in reducing the
inflammation locally whereas systemic immune suppression
by MSCs was mediated by the switch of the inflammatory
Th1/Th17 profile towards a more Th2 response. Also in
the amelioration of TNBS-induced colitis, the importance
of PGE2 produced by human adMSCs was demonstrated
[40]. Furthermore, in addition to a therapeutic efficacy of
bmMSCs, Tanaka et al. [49] showed in a DSS model a
decrease in mRNA expression of inflammatory mediators
TNF-α, IL-1β, and COX-2 in the rectum of rats treated
with bmMSCs compared to control values, again suggesting
that this might be a pivotal mechanism explaining the
immunosuppressive effects of MSCs.
7. Inducible Nitric Oxide Synthase (iNOS) and
Indoleamine 2,3-Dioxygenase (IDO)
Nitric oxide (NO) is an important signaling molecule and
is involved in tissue homeostasis and immunoregulatory
functions. iNOS is expressed by murine MSCs as a result of
stimulation with IFN-γ combined with TNF-α, IL-1α, or IL-
1β [50]. Immunosuppression is achieved when high levels
of NO are released, but no immunosuppression is seen with
MSCs derived from INOS−/− or IFNγR1−/− mice. In addi-
tion, only wild-type MSCs but not iNOS−/−- or IFNγR1−/−-
MSCs prevented graft-versus-host disease and delayed-type
hypersensitivity in mice. Interestingly, iNOS−/−-MSCs even
worsened this delayed-type hypersensitivity. These results
suggest that the combination of iNOS and IFN-γ is crucial
to achieve immunosuppression [50]. Substantiating this
theory, a recently published paper on the therapeutic effect
of aspirin in TNBS-induced colitis [51] demonstrated that
NO-releasing aspirin, in contrast to regular aspirin, COX-1
inhibitors and SC-560, accelerated colonic healing character-
ized by a down-regulation of COX-2, iNOS, IL-1β, and TNF-
α mRNAs.
The mechanism of MSC-mediated immunosuppression
is different in mice and humans. While murine MSCs use
predominantly iNOS to control immune responses, human
MSCs mainly utilize indoleamine 2,3-dioxygenase (IDO), an
immunoregulatory enzyme regulating tryptophan levels, and
express only very low levels of iNOS [52]. However, both
mouse MSCs and human MSCs need IFN-γ, combined with
TNF-α, IL-1α, or IL-1β, in the induction of the suppression
of immune cells such as T cells and NK cells through these
enzymes [53, 54].
In addition, to inhibit T-cell proliferation, MSCs might
have to be in contact with the T cells, as shown by Ren et al.
[50, 52], since this inhibition was abolished when these cells
were separated by transwells. Therefore, MSCs express T-cell
specific chemokines to attract immune cells and may thereby
effectuate their immune response through soluble factors.
Recently, gMSCs were found to suppress PBMC
proliferation in the same manner as bmMSCs by Zhang
et al. [23] Comparable to bmMSCs, gMSCs induce several
immunosuppressive factors in response to IFN-γ, including
IL-10, COX-2, iNOS, and IDO. IDO and IL-10, but not COX-
2 or iNOS, which were upregulated by IFN-γ, contributed
to the gMSC-mediated suppression of PBMC proliferation.
A protective effect of gMSCs in a DSS model with C57BL/6
mice was also observed, exemplified by the fact that gMSCs
significantly suppressed mucosal ulceration of the colon,
ameliorated transmural inflammation, and decreased wall
thickness, thereby restoring the colonic tissue homeostasis.
In the nontreated DSSmice, an infiltration of CD4+ cells was
seen in the mucosal and muscularis layers and an increased
expression of IL-6, IFN-γ, and IL-17 was found in the
inflamed colons. Systemic infusion of gMSCs was found to
diminish the amount of CD4+ cells in the colon and to
decrease the levels of inflammatory cytokines at the intestinal
mucosa. In addition, anti-inflammatory cytokine IL-10 levels
were increased and an influx of Tregs was seen.
Our group [55] demonstrated that IFN-γ activation of
MSCs (iMSCs) before administration of these MSCs to
mice enhanced their capacity to inhibit Th1 inflamma-
tory responses. Stimulation of human MSCs with IFN-γ
increased their expression of IDO and activation of mouse
MSC with this cytokine induced higher iNOS levels. In a
DSS model, we showed that mice treated with human iMSCs
have a less severe mucosal mononuclear cell infiltration and
reduced disruption of crypt architecture, compared to mice
treated with nonprestimulated MSCs. In addition, BALB/c
mice treated with mouse iMSCs after the induction of colitis
with TNBS gained 2,5% body weight at sacrifice compared
to a decrease in body weight of 1,3% in nonactivated MSC-
treated animals and even 4,9% in the PBS group. In both
experimental colitis models, TNF-α and IL-6 levels were
elevated but treatment with iMSCs was accompanied by a
strong reduction in the amount of TNF-α and IL-6 in the
colon.
8. Clinical Trials onMSC Treatment of
Luminal and Fistulizing CD
Several papers on clinical trials using MSCs as treatment
for CD and perianal fistulas have been published [56–59].
All these studies demonstrated that the administration of
autologous or allogeneic MSCs is safe and feasible and some
studies have suggested a potential therapeutic effect of these
cells. In our hands [56], three out of nine patients with lumi-
nal CD treated with autologous bmMSCs showed clinical
response, defined as a decrease of 70 or more points in CD
Activity Index (CDAI), 6 weeks afterMSC infusion. However,
also three out of nine patients required surgery 7, 12, and
14 weeks, respectively, after MSC injection due to disease
worsening. In order to assess mucosal changes, biopsies of
inflamed colonic mucosa were taken at week 0 and week 6
afterMSC infusion. A trend of lower CD4+ T cells and higher
CD4+CD127+ regulatory T cells was observed in the biopsies
taken at week 6 compared to the biopsies at week 0. In vitro,
the proliferation of PBMCs in the presence of autologous
bmMSCs derived from patients with CDwas reduced in a cell
dose-dependent manner similar to bmMSCs from healthy
Journal of Allergy 5
donors, indicating a normal immunosuppressive activity of
the CD patient-derived MSCs. Moreover, in the presence of
immunosuppressive drugs such as azathioprine, methotrex-
ate, 6-mercaptopurine, and infliximab, MSCs maintained
their multilineage differentiation potential and their ability
to suppress proliferation of PBMCs in vitro was not altered.
In addition, the neutralization of TNF-α by the anti-TNF-
α agent infliximab did not hamper the suppressive effect
of MSCs [60]. Apparently, an optimal treatment protocol
of luminal CD has not been achieved yet but comedication
seems not to affect the functional activity of the MSCs.
Encouraging results have been obtained from phase I and
II trials in patients with fistulizing CD. In one study, a total
of nine fistulas in four patients were injected with adMSCs
to demonstrate the safety of the local application of MSCs
in fistulizing CD [57]. Although the study was not designed
to determine effectiveness, 75 percent of the fistulas treated
with adMSCs were considered healed after eight weeks and
no adverse events were observed. This trial was followed by a
phase II study, sponsored by Cellerix, to evaluate the efficacy
and safety of adMSCs treatment in 49 adult patients with
complex perianal fistulas from cryptoglandular disease (n =
35) or CD (n = 14) [58]. Patients were randomly assigned to
either intralesional treatment with fibrin glue alone or with
fibrin glue plus 20 million adMSCs. When the fistulas were
not healed after eight weeks, a second dose of fibrin glue or
40 million adMSCs plus fibrin glue was injected. In four out
of the 25 patients (16%) who received fibrin glue without
MSCs, healing of fistulas was observed compared to 17 out of
the 24 patients (71%) who received fibrin glue plus adMSCs.
In both the cryptoglandular disease and the fistulizing CD
group efficacy was observed. In another trial, 10 patients
refractory to or unsuitable for current available therapies for
fistulizing CDwere locally injected with autologous bmMSCs
at four-week intervals [59]. Each patient underwent a
median of four injections with approximately 20 million
bmMSCs per time as long as autologous bmMSCs were
available. In all patients, an improvement of CDAI and
perianal disease activity index (PDAI) was observed and
rectal mucosal healing was induced. In addition, fistulas
closed completely in seven out of the ten patients without
any adverse events.
Although only one clinical trial on MSCs for the
treatment of luminal CD has been published, a discrepancy
in efficacy between systemic infusion of MSCs for luminal
CD and local injection for the treatment of fistulizing CD
might be observed. It is thought that after intravenous
administration, MSCs migrate to the site of disease to
modulate immune responses and contribute to the tissue
repair. In an experimental colitis model, Gonzalez-Rey et
al. [41] showed homing of intraperitoneal injected human
adMSCs to inflamed colon, but not to noninflamed colon. In
addition, Duijvestein et al. [55] observed this specific homing
using human bm-iMSCs. However, iMSCs were found across
a wide array of tissues and only a small proportion of iMSCs
was detected in the diseased intestine, suggesting that may be
not all cells survive and that additional mechanisms such as
soluble factors might contribute to the immunosuppression.
One could speculate that compared to systemic infusion,
higher numbers of cells reach the damaged tissue when
injected locally and therefore are more likely to perform
their immunosuppressive and tissue regenerative functions
directly or via soluble factors. Randomized controlled trials
with a sufficient number of patients are needed in order to
prove the actual efficacy of MSCs in the treatment of luminal
and fistulizing CD.
9. MSCs and Their Immunomodulatory
Complexity
Although encouraging results from clinical trials on fis-
tulizing CD have been published, some reservations should
be made since similar phase III studies in patients with
severe refractory intestinal graft-versus-host disease (GvHD)
demonstrated no effectiveness of MSC treatment as opposed
to the initial phase II studies [61]. This lack of efficacy
might be procedural since Franc¸ois et al. [62] indicated
that cryopreserved MSCs, used in clinical trials, could not
suppress T-cell proliferation in vitro after thawing. However,
after 24 hours of culture, the immunosuppressive effect of
these postthaw MSCs was restored to a level comparable to
MSCs cultured for 7 days. In addition, IFN-γ stimulated
freshly thawed MSCs expressed very low levels of IDO
compared to cultured MSCs, which might be an explanation
for the diminished immunosuppressive properties of these
MSCs. Although in clinical trials mostly MSCs passages 1
or 2 are used, MSCs do lose their typical spindle shape
morphology and their proliferation rate seems to decrease
with increasing passage number. MSCs from younger donors
seem to maintain these characteristics up to higher passages
then MSCs from older donors [63–65]. Furthermore, in a
recently published paper, Li et al. [66] showed that MSCs
have the capacity to promote immune responses instead
of suppressing them. MSCs were cocultured with freshly
isolated splenocytes in the presence of anti-CD3 to stimulate
the latter to produce IFN-γ and TNF-α. At high splenocyte,
MSC ratios T-cell proliferation was inhibited, whereas at
lower densities this proliferation was found to be enhanced.
This suggests that depending on the relative concentration
of T cells and MSCs, MSCs can either have an immuno-
suppressive or an immunostimulatory effect. Remarkably,
MSCs enhanced T cell proliferation when splenocytes were
stimulated with low concentrations of anti-CD3, which
indicates that insufficient levels of inflammatory cytokines
most probably caused this effect. Interestingly, MSCs pre-
treated with IFN-γ and TNF-α before cocultring them with
splenocytes inhibited T-cell proliferation regardless of the
number of T cells present. This clearly indicates that the level
of proinflammatory cytokines determines whether MSCs act
as immune suppressors or enhancers. Furthermore, iNOS−/−
MSCs cocultured with splenocytes were not only unable to
suppress T-cell proliferation, they even caused a dramatic
elevation of the immune response. Intriguingly, IFN-γ and
TNF-α pretreatment of iNOS−/− MSCs also enhanced the
proliferation of T cells, once more illustrating the complexity
of MSC-mediated immunomodulation. These findings are
of high importance when considering MSCs as a new
treatment option, especially in diseases with an alternating
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severity of inflammation such as CD. MSCs may switch
from immunosuppressive cells to immunoenhancing cells in
the absence of sufficiently high levels of proinflammatory
cytokines, which could possibly lead to a flareup instead of
a complete remission in patients with a mild course of CD.
Although the neutralization of TNF-α with the anti-TNF-
α agent infliximab did not hamper the suppressive effect of
MSCs in vitro [60], nothing is known about the effect of anti-
TNF-α agents on MSCs in vivo.
10. Concluding Remarks
The ability of MSCs to suppress immune responses, partic-
ularly T-cell proliferation, combined with their potential to
actively participate in tissue repair provides a strong rationale
for the use of MSCs as a new treatment option in diseases
characterized by inflammation and severe tissue damage,
such as CD. Several studies have shown the ability of MSCs to
alter cytokine secretion profiles of DCs, naı¨ve and effector T
cells, and NK cells to induce an anti-inflammatory or regula-
tory milieu in vitro and in vivo. However, recently published
papers attribute the immunosuppressive capacity of MSCs to
soluble factors produced byMSCs when stimulated by IFN-γ
or TNF-α, such as PGE2, iNOS, and IDO.
The fact that MSCs are poor APCs and do not express
MHC class II or costimulatory molecules in a resting state
suggests that allogeneic MSCs could be used for clinical
applications. In addition, the possibility to use allogeneic
MSCs gives rise to a possible stock production with “off
the shelf-”treatment potential. Several clinical studies have
been performed using both autologous and allogeneic MSCs
as a treatment for patients with luminal CD or perianal
fistulas. Although encouraging results are obtained from
these phase I and II trials, the discouraging results of two
phase III studies with MSCs in severe refractory intestinal
GvHD are a serious drawback. Further research into the
molecular mechanisms through which MSCs act is necessary
to understand the complexity of the immunomodulatory
effects of MSCs and to develop a new treatment modality for
patients with refractory CD and/or perianal fistulas.
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